

References

I-5060

1. Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. *Cancer*. Jul 01 2008; 113(1): 5-21. PMID 18473355.
2. Bohnenberger H, Dinter H, König A, et al. Neuroendocrine tumors of the thymus and mediastinum. *J Thorac Dis*. Nov 2017; 9(Suppl 15): S1448-S1457. PMID 29201448.
3. Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. *JAMA Oncol*. Oct 01 2017; 3(10): 1335-1342. PMID 28448665.
4. Sorbye H, Strosberg J, Baudin E, et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. *Cancer*. Sep 15 2014; 120(18): 2814-23. PMID 24771552.
5. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. *Pancreas*. Apr 2009; 38(3): 255-8. PMID 19066493.
6. Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. *Endocr Relat Cancer*. Apr 2013; 20(2): 187-96. PMID 23319495.
7. Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. *Ann Oncol*. Aug 2015; 26(8): 1604-20. PMID 25646366.
8. Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). *Gut*. Jan 2012; 61(1): 6-32. PMID 22052063.
9. Berg K, Leyden J, Goldstein G, et al. Neuroendocrine tumor European patient experience: results from the first global NET patient survey - a collaboration between the International Neuroendocrine Cancer Alliance and Novartis [abstract]. *Endocrine Abstracts*. 2015;37:EP1139.

10. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. *Cancer*. Feb 15 2000; 88(4): 770-6. PMID 10679645.
11. Strosberg J. Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs). *Gastrointest Cancer Res*. Jul 2013; 6(4 Suppl 1): S10-2. PMID 24312683.
12. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med*. Feb 10 2011; 364(6): 514-23. PMID 21306238.
13. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. *Lancet*. Mar 05 2016; 387(10022): 968-977. PMID 26703889.
14. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet*. Dec 10 2011; 378(9808): 2005-2012. PMID 22119496.
15. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med*. Feb 10 2011; 364(6): 501-13. PMID 21306237.
16. Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. *Neuroendocrinology*. 2016; 103(2): 186-94. PMID 26731334.
17. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. Jun 2014; 99(6): 1915-42. PMID 24893135.
18. Lefebvre M, Foulkes WD. Pheochromocytoma and paraganglioma syndromes: genetics and management update. *Curr Oncol*. Feb 2014; 21(1): e8-e17. PMID 24523625.

19. Hamidi O, Young WF, Gruber L, et al. Outcomes of patients with metastatic pheochromocytoma and paraganglioma: A systematic review and meta-analysis. *Clin Endocrinol (Oxf)*. Nov 2017; 87(5): 440-450. PMID 28746746.
20. Hamidi O, Young WF, Iñiguez-Ariza NM, et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. *J Clin Endocrinol Metab*. Sep 01 2017; 102(9): 3296-3305. PMID 28605453.
21. Pheochromocytoma and Paraganglioma Treatment. National Cancer Institute. <https://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq>. Accessed May 29, 2023.
22. Gunawardane PTK, Grossman A. Pheochromocytoma and Paraganglioma. *Adv Exp Med Biol*. 2017; 956: 239-259. PMID 27888488.
23. Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (¹³¹I-MIBG): a comprehensive review of 116 reported patients. *J Endocrinol Invest*. Dec 1997; 20(11): 648-58. PMID 9492103.
24. Bleeker G, Schoot RA, Caron HN, et al. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis. *Eur J Nucl Med Mol Imaging*. Oct 2013; 40(11): 1711-7. PMID 23921531.
25. Ayala-Ramirez M, Feng L, Habra MA, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. *Cancer*. Jun 01 2012; 118(11): 2804-12. PMID 22006217.
26. Fliedner SM, Lehnert H, Pacak K. Metastatic paraganglioma. *Semin Oncol*. Dec 2010; 37(6): 627-37. PMID 21167381.
27. Ayala-Ramirez M, Chougnet CN, Habra MA, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. *J Clin Endocrinol Metab*. Nov 2012; 97(11): 4040-50. PMID 22965939.
28. Novartis. Novartis provides update on production of radioligand therapy medicines. May 5, 2022; <https://www.novartis.com/news/media-releases/novartis-provides-update-production-radioligand-therapy-medicines>. Accessed on May 28, 2023.

29. Novartis. Novartis resumes production and delivery of radioligand therapy medicines ahead of schedule. June 30, 2022; <https://www.novartis.com/news/media-releases/novartis-resumes-production-and-delivery-radioligand-therapy-medicines-ahead-schedule>. Accessed May 29, 2023.
30. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors. *N Engl J Med*. Jan 12 2017; 376(2): 125-135. PMID 28076709.
31. Food and Drug Administration, Center for Drug Evaluation and Research. Application Number: 208700Orig1s000 Multi-Disciplinary Review. Addendum to Review, NDA 208700. 2018; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208700Orig1s000MultidisciplineR.pdf. Accessed May 29, 2023.
32. Novartis Inc. Lutathera (lutetium Lu 177 dotatate) injection, for intravenous use administration of Lutathera (Prescribing Label). 2018; https://hcp.lutathera.com/wp-content/uploads/2019/09/LUTATHERA_lutetium_Lu_177_dotatate_FDA_Prescribing_Information.pdf. Accessed May 29, 2023.
33. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [¹⁷⁷Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol*. May 01 2008; 26(13): 2124-30. PMID 18445841.
34. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-Term Efficacy, Survival, and Safety of [¹⁷⁷Lu-DOTA 0 ,Tyr 3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. *Clin Cancer Res*. Aug 15 2017; 23(16): 4617-4624. PMID 28428192.
35. Mitjavila M, Jimenez-Fonseca P, Belló P, et al. Efficacy of [¹⁷⁷Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. *Eur J Nucl Med Mol Imaging*. Jul 2023; 50(8): 2486-2500. PMID 36877234.
36. Zidan L, Iravani A, Oleinikov K, et al. Efficacy and Safety of ¹⁷⁷Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study. *J Nucl Med*. Feb 2022; 63(2): 218-225. PMID 34049983.

37. Food and Drug Administration. NDA/BLA Multi-Disciplinary Review and Evaluation: AZEDRA, I 131-MIBG [NDA 209607]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209607Orig1s000MultidisciplineR.pdf. Accessed May 28, 2023.
38. Progenics Pharmaceuticals. Prescribing Label: AZEDRA (iobenguane I 131) injection, for intravenous use. March 2021; <https://www.azedra.com/full-prescribing-information.pdf>. Accessed May 29, 2023.
39. Prado-Wohlwend S, Del Olmo-García MI, Bello-Arques P, et al. Response to targeted radionuclide therapy with [131 I]MIBG AND [177 Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review. *Front Endocrinol (Lausanne)*. 2022; 13: 957172. PMID 36339441.
40. Satapathy S, Mittal BR, Bhansali A. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'. *Clin Endocrinol (Oxf)*. Dec 2019; 91(6): 718-727. PMID 31569282.
41. Severi S, Bongiovanni A, Ferrara M, et al. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. *ESMO Open*. Aug 2021; 6(4): 100171. PMID 34139487.
42. Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. *J Clin Endocrinol Metab*. Sep 01 2017; 102(9): 3278-3287. PMID 28605448.
43. Love C, Desai NB, Abraham T, et al. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. *Clin Nucl Med*. Jun 01 2022; 47(6): 503-511. PMID 35507433.
44. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed May 29, 2023.